Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 201528-06-2023
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement of the Notice of Postal BallotStrides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015Strides Pharma Science Ltd - 532531 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Notice of Postal BallotStrides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship LtdBuy Strides Pharma Sciences; target of Rs 450: Sharekhan
Sharekhan is bullish on Strides Pharma Sciences Ltd has recommended buy rating on the stock with a target price of Rs 450 in its research report dated June 01, 2023.Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings Call transcript pertaining to Audited Financial Results for the quarter and year ended March 31, 2023.Strides Pharma Science Ltd - 532531 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended March 31, 2023